Intelligence / Healthtech / PMA Approvals / Novocure, GMBH
Approvalsdevice change approved (PMA)18 Sept 2026
Novocure, GMBH
18 Sept 2026: Device change approved (PMA) · Novocure GmbHs Optune Gio. Recorded in the openFDA device PMA data.
- Decided
- 18 Sept 2026
- Device
- Novocure GmbHs Optune Gio
- Specialty
- Neurology
- Type
- Supplement (Normal 180 Day Track No User Fee)
- Reason
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Reference
- P100034 S045
- Location
- Baar
What this signal means
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Novocure, GMBH
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
More in Neurology
PMA Approvals
24 OctStryker Neurovasculardevice change approved (PMA) · Neuroform Atlas® Stent SystemApprovals23 OctCerenovus, INC.device change approved (PMA) · TRUFILL n-BCA Liquid Embolic SystemApprovals16 OctBalt USA, LLCdevice change approved (PMA) · SQUID Liquid Embolic Agent (LEA)Approvals15 OctBoston Scientific Corpdevice change approved (PMA) · Vercise DBS SystemsApprovals14 OctEv3 Neurovasculardevice change approved (PMA) · Onyx Liquid Embolic System (Onyx LES)Approvals1 OctPramand, LLCdevice change approved (PMA) · CraniSeal Dural SealantApprovals
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.